Stryker Corp. (NYSE:SYK)‘s stock had its “hold” rating reissued by research analysts at Needham & Company LLC in a report issued on Sunday.

The analysts wrote, “Analysts Conflictied on These Healthcare Names: Stryker (NYSE: SYK), Athersys (NASDAQ: ATHX) and Bio-Path Holdings (NASDAQ: BPTH) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=b4868bde84&wpp_id=459998’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Conflictied on These Healthcare Names: Stryker (NYSE: SYK), Athersys (NASDAQ: ATHX) and Bio-Path Holdings (NASDAQ: BPTH)”

A number of other brokerages have also recently commented on SYK. Zacks Investment Research cut Stryker Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, September 27th. Brean Capital reissued a “buy” rating and set a $125.00 target price (up previously from $121.00) on shares of Stryker Corp. in a report on Monday, July 25th. Jefferies Group reissued a “hold” rating and set a $120.00 target price (up previously from $113.00) on shares of Stryker Corp. in a report on Monday, July 25th. Credit Suisse Group AG reissued an “outperform” rating and set a $124.00 target price (up previously from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. Finally, Piper Jaffray Cos. upped their price target on Stryker Corp. from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corp. currently has an average rating of “Hold” and an average price target of $122.86.

Analyst Recommendations for Stryker Corp. (NYSE:SYK)

Shares of Stryker Corp. (NYSE:SYK) opened at 110.36 on Friday. Stryker Corp. has a 52 week low of $86.68 and a 52 week high of $123.55. The company’s 50 day moving average price is $115.24 and its 200-day moving average price is $114.92. The company has a market capitalization of $41.32 billion, a price-to-earnings ratio of 25.12 and a beta of 0.86.

Stryker Corp. (NYSE:SYK) last announced its earnings results on Thursday, October 27th. The medical technology company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The business earned $2.83 billion during the quarter, compared to analysts’ expectations of $2.81 billion. During the same quarter in the prior year, the firm earned $1.25 earnings per share. The business’s revenue was up 17.1% compared to the same quarter last year. Analysts anticipate that Stryker Corp. will post $5.78 earnings per share for the current fiscal year.

In other Stryker Corp. news, VP Yin C. Becker sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of $114.03, for a total transaction of $1,368,360.00. Following the transaction, the vice president now owns 28,939 shares of the company’s stock, valued at $3,299,914.17. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Yin C. Becker sold 1,111 shares of the firm’s stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $117.00, for a total value of $129,987.00. Following the transaction, the vice president now directly owns 16,939 shares in the company, valued at approximately $1,981,863. The disclosure for this sale can be found here. 7.80% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Blue Chip Partners Inc. raised its position in shares of Stryker Corp. by 0.3% in the second quarter. Blue Chip Partners Inc. now owns 1,757 shares of the medical technology company’s stock valued at $211,000 after buying an additional 6 shares during the last quarter. Washington Trust Bank raised its position in shares of Stryker Corp. by 0.5% in the second quarter. Washington Trust Bank now owns 3,040 shares of the medical technology company’s stock valued at $364,000 after buying an additional 15 shares during the last quarter. Wetherby Asset Management Inc. raised its position in shares of Stryker Corp. by 0.3% in the second quarter. Wetherby Asset Management Inc. now owns 6,242 shares of the medical technology company’s stock valued at $748,000 after buying an additional 18 shares during the last quarter. Douglas Lane & Associates LLC raised its position in Stryker Corp. by 0.7% in the second quarter. Douglas Lane & Associates LLC now owns 2,945 shares of the medical technology company’s stock worth $353,000 after buying an additional 20 shares in the last quarter. Finally, Wade G W & Inc. raised its position in Stryker Corp. by 1.0% in the third quarter. Wade G W & Inc. now owns 2,230 shares of the medical technology company’s stock worth $260,000 after buying an additional 22 shares in the last quarter. 75.29% of the stock is currently owned by institutional investors.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.